Obstacles remain for patients with blood cancers

pharmafile | August 20, 2009 | News story | Research and Development, Sales and Marketing |  NICE, blood cancer 

Related Content

Combination treatments: Takeda’s Implementation Framework and the broader landscape

Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …

ViroCell Biologics and AvenCell Therapeutics partner to accelerate allogeneic CAR-T therapy development

ViroCell Biologics has announced a new manufacturing collaboration with AvenCell Therapeutics to produce a high-yield …

Sarclisa recommended for EU approval in newly diagnosed multiple myeloma

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi’s …

The Gateway to Local Adoption Series

Latest content